Background and objectives: Gastrinomas are the most prevalent functioning neuroendocrine tumors (NET) in multiple endocrine neoplasia type 1 (MEN1). Guidelines suggest medical therapy in most patients, but surgery may be considered in a subgroup. Currently, factors to guide management are necessary. This population-based cohort study assessed prognostic factors of survival in patients with MEN1-related gastrinomas.
[2.1-36.7]), gastroduodenoscopy suspicious for gastric NETs (HR 12.7; ), and multiple concurrent NETs (HR 5.9; [1. 2-27.7] ).
Conclusion: Life expectancy of patients with MEN1 gastrinoma is reduced. FSG levels and pancreatic NETs ≥2 cm are prognostic factors. FSG levels might guide surveillance intensity, step-up to additional diagnostics, or provide arguments in selecting patients who might benefit from surgery. Gastrinomas are the most frequently encountered functioning dpNETs and occur in approximately 30% of patients with MEN1. 3 These tumors produce gastrin which induces gastric acid hypersecretion and subsequently leads to ulcerative peptic disease and gastrointestinal bleeding, known as the Zollinger-Ellison syndrome. 4 MEN1-related gastrinomas are generally located in the duodenal submucosa and are rarely found in the pancreas. 5, 6 Duodenal gastrinomas are often small (<1 cm), multiple and accompanied by pancreatic neuroendocrine tumors (pNETs). 6 Approximately 70% to 80% of surgically treated patients have lymph node metastases, and 10% present with synchronous liver metastases. 7, 8 Gastric acid hypersecretion-related complications used to be the leading cause of death in patients with MEN1 having gastrinomas before the widespread use of proton pump inhibitors (PPIs). 9, 10 Nowadays, compared with the general population, patients with MEN1 have a seriously decreased life expectancy mainly caused by malignant dpNETs. 2 However, the reported prognosis of patients with MEN1 gastrinoma varies widely. 8, [11] [12] [13] In the French cohort, studied from 1956 to 2005, gastrinomas have been reported as an independent risk factor for death. 9 Actual data on MEN1 gastrinoma survival are scarce and survival rates are difficult to interpret since patients are diagnosed and treated differently among studies. In addition, the understanding that MEN1 gastrinomas mostly originate in the duodenum instead of the formerly assumed pancreatic origin, emphasizes the need for new studies. Besides, data regarding the long-term natural history are important, because guidelines suggest symptomatic management using PPIs in the majority of patients. 14, 15 Nevertheless, the only potentially curative oncological treatment remains surgery. Pancreaticoduodenectomy offers the possibility to achieve a biochemical cure for MEN1-related duodenal gastrinomas. 8 However, controversies exist regarding the timing and the extent of surgery, considering the unpredictable tumor course and morbidity associated with extensive surgery. 14, 15 Therefore, the necessity of prognostic factors to guide therapy has recently been underscored. 16 Since gastrinomas are hormone producing tumors, we hypothesized that, besides known dpNET-related prognostic factors such as pNET size and liver metastases, gastrin levels might predict survival in this population. 17 Therefore the present study aims to assess prognostic factors and survival in patients with MEN1 having gastrinomas.
| MATERIALS AND METHODS

| Study design
Patients were selected from the national Dutch MEN1 database from the DutchMEN Study Group (DMSG). 18 
| Patient selection
The diagnosis of gastrinomas in patients with MEN1 was challenging, since the reference standard, provocative tests using secretin, is not widely available and routine measurements of basal acid output at gastroduodenoscopy were not routinely performed. Therefore, based on stringent criteria we aimed to identify those patients of whom we were confident of having gastrinomas, also using subsequently elevated fasting serum gastrin (FSG) levels. Gastrinoma diagnosis was based on (a) pathology reports of gastrin immunohistochemistry positive tumors or (b) elevated FSG levels, or (c) gastroduodenoscopy suspicious for gastrinoma, or a combination of these. Serum gastrin reference values were obtained from all UMCs over the study period. FSG levels were calculated as a factor of the upper limit of normal VAN BEEK ET AL.
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(ULN) of the reference values. Gastrinoma diagnosis was considered certain when FSG levels were increased more than a 10-fold of ULN (regardless of PPI use) or probable when FSG measurements were elevated consecutively (a) more than a two-fold of ULN (without PPI) without consecutive FSG levels <2x ULN during follow-up or (b) more than a five-fold (under PPI) without consecutive FSG levels <5x ULN during follow-up, without surgery or the start of systemic antitumor therapy (Table S1 ). Pathological gastrinoma diagnosis was established if immunohistochemistry of tumor tissue stained positive for gastrin, in the presence of hypergastrinemia. MEN1-related NETs at the moment of gastrinoma diagnosis were diagnosed according to pathology reports. 2 If no pathology reports were available, imaging results were used for diagnosis as previously described. 19 Gastric NETs were also diagnosed using gastroduodenoscopies. The size of the largest pNET on conventional imaging was used for further analysis.
| Clinical definitions
| Treatment
Patients were treated medically by PPIs to prevent acid-related complications by somatostatin analogs or surgically to prevent metastatic disease. Treatment regimen was decided by the treating 
| Outcome measures
The primary outcomes were 5-and 10-year overall survival (OS).
Possible prognostic factors at gastrinoma diagnosis were analyzed for influence on OS. The date of death or date of last follow-up was used for analysis.
| Statistical analysis
Descriptive statistics were reported as mean (standard deviation [SD]) or median (range), as appropriate, or as numbers (percentages). Differences in means were tested using t tests. Survival curves were plotted according to the Kaplan-Meier method and survival probabilities were obtained. 20 was observed in 193 patients (54%), regardless of PPI use. In 114 patients (32%), FSG levels were >1x ULN in the absence of PPI. One hundred patients (28%) had FSG levels >2x ULN under PPI.
Ten-fold increased FSG levels were longitudinally observed in 45 patients (13%).
| Patient characteristics
Demographic and clinical characteristics are described in Table 1 .
Sixty-three patients with gastrinoma (16%) were identified in the 
| Survival of patients with MEN1 gastrinoma
OS rates of patients with MEN1 gastrinoma after 5 and 10 years were 83% and 65%, respectively ( Table 2 ; Figures 1A and S2A ). Five and 10-year OS rates for patients with MEN1 having FSG measurements not indicative for a gastrinoma were 93% and 87%, respectively ( Figures 1B and S2B ). Patient with gastrinomas were older than patients without gastrinomas (51 vs 39 years, P < .001).
Ten-year OS rates were 65% vs 81% for age and gender matched MEN1 patients without gastrinomas ( Figures 1C and S2C ).
| Prognostic factors for OS
Prognostic factors for OS are shown in Table 3 In addition, patients with synchronous liver metastases were included in our study. Liver metastases, either NF-pNET or gastrinoma related, are associated with survival. 7, 11, 13, 17, 21 Although the OS rate was lower, the age of death (58 years) was slightly higher than in previous series (55-56 years). [10] [11] [12] Initial FSG levels were associated OS, also after adjusting for age.
More specifically, OS decreased as FSG levels increased. Ito et al 10 described very high FSG levels (>20-fold elevated) more often in deceased patients. We observed a significantly increased HR for death in patients with FSG levels higher than 20x ULN. In line, we observed a HR of 2.66 and a 10-year OS of 66% for patients with FSG levels between 10 and 20x ULN. We believe that the outcomes of this analysis were not statistically significant due to the low number of patients and events in this subgroup. NIH series observed higher FSG levels in patients with an aggressive disease course and in patients with liver metastases, although no survival analysis was conducted. 7, 13 The only study focusing on initial FSG levels and survival in patients with MEN1 from the NIH, did not find a significant correlation in MEN1 gastrinoma patients (log rank P = .068). 22 In this study of 53 patients with MEN1 gastrinoma, only four deaths were observed. 22 Compared with our study, in this NIH series other diagnostic criteria were applied probably influencing the case mix and, in addition, the study period was a decade earlier.
Pancreatic NET ≥2.0 cm on imaging and liver metastases at gastrinoma diagnosis were associated with decreased OS. Formerly, gastrinomas were generally regarded as pNETs causing liver metastases and death. However, studies including gastrin immunohistochemistry and pathological series report the predominant duodenal origin. 5, 8, 23 Therefore, it can be hypothesized that these patients have decreased OS because of a concurrent NF-pNET ≥2.0 cm instead of a pancreatic gastrinoma. Recently, the acceptable prognosis of NF-pNETs <2 cm has been highlighted. 19, 24, 25 The decreased survival of patients with MEN1 having liver metastases is in line with other studies. 11, 13 Nevertheless, the exact cause of death in patients with MEN1 gastrinoma having concurrent large (NF)-pNETs remains challenging.
This study is limited by the challenges of gastrinoma diagnosis in patients with MEN1. Current guidelines recommend the combination of hypergastrinemia and basal gastric acid hypersecretion (pH < 2). 14, 15 Gastrinoma diagnosis frequently differs from these criteria, because of the lack of gastric pH measurement, the unavailability of secretin testing and the use of immunohistochemistry and imaging as alternatives. 26 In daily clinical practice of the 14, 15 Although 52% had a pNET at the moment of gastrinoma diagnosis, only 19% of all patients in this cohort had pNETs >2.0 cm on cross-sectional imaging. Especially, in the coexistence of hypergastrinemia and pNETs ≥2.0 cm, the optimal surgical strategy is hard to establish. Merging the need for pancreaticoduodenal resections to achieve biochemical cure on the one hand and the scarcity of data regarding postoperative complications and long-term oncological outcomes after pancreaticoduodenal resections on the other, future studies should address these topics to come to meaningful advice. 28 In conclusion, life expectancy in patients with MEN1 having gastrinomas is reduced compared with other studies. OS was associated with initial FSG levels ≥20x ULN, a pNET ≥2.0 cm on conventional imaging, synchronous liver metastases, multiple concurrent NETs, and gastroduodenoscopy suspicious for gastric NET in patients with MEN1. OS decreases as FSG levels increase, starting from ≥10x ULN. Therefore, FSG levels might provide a valuable tool to guide surveillance intensity, step-up to additional diagnostic modalities or provide arguments in selecting those patients who might benefit from surgery.
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